Antares pharma inc.

Delaware . 1-32302 . 41-1350192 (State or other jurisdiction. of incorporation) (Commission. File Number) (I.R.S. Employer. Identification No.) 100 Princeton South ...Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced it has entered into an exclusive licensing agreement with Antares Pharma, Inc. to commercialize TLANDO in the United States. TLANDO is an oral testosterone product for testosterone replacement therapy ("TRT") in ...Antares Pharma, Inc. (Exact Name of Registrant Specified in Charter) Delaware (State or Other. Jurisdiction of. Incorporation) 1-32302 (Commission File. Number) 41-1350192 (I.R.S. Employer. Identification No.) 250 Phillips Blvd., Suite 290, Ewing, NJ . 08618 (Address of Principal Executive Offices) (Zip Code) Registrant’s telephone number, including area …Dec 15, 2021 · Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...

“At one minute following 11:59 p.m., Eastern Time, on May 23, 2022, the Offer expired. Equiniti Trust Company, the depository and paying agent for the Offer, advised Purchaser that, as of the expiration of the Offer, a total of 139,371,158 Shares were validly tendered and not validly withdrawn pursuant to the Offer, representing approximately 81.56% of …Tiberend Strategic Advisors, Inc. Jason Rando. (212) 827-0020. [email protected]. Share. Antares Pharma, Inc. (NYSE Amex: AIS) today announced that it has licensed to Pfizer Inc.’s Consumer Healthcare Business Unit one of its drug delivery technologies to develop an undisclosed product on an exclusive basis for North America.Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in ...

Dec 15, 2021 · Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ... Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...

0. (Reuters) -Halozyme Therapeutics Inc is bolstering its drug delivery platform with a $960 million all-cash deal for specialty pharmaceutical company Antares Pharma Inc, the companies said on Wednesday. San Diego-based Halozyme offers delivery technology that enables high volumes of a drug to be injected under the skin, potentially …Antares Pharma, Inc. (Exact Name of Registrant Specified in Charter) Delaware (State or Other. Jurisdiction of. Incorporation) 1-32302 (Commission File. Number) 41-1350192 (I.R.S. Employer. Identification No.) 250 Phillips Blvd., Suite 290, Ewing, NJ . 08618 (Address of Principal Executive Offices) (Zip Code) Registrant’s telephone number, including area …Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. The Company develops, manufactures, and commercializes, for itself or with partners, therapeutic products ...0. (Reuters) -Halozyme Therapeutics Inc is bolstering its drug delivery platform with a $960 million all-cash deal for specialty pharmaceutical company Antares Pharma Inc, the companies said on Wednesday. San Diego-based Halozyme offers delivery technology that enables high volumes of a drug to be injected under the skin, potentially …

SAN DIEGO and EWING, N.J., April 13, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") and Antares Pharma, Inc. (NASDAQ: ATRS) ("Antares") today announced that the...

ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) ...

18. 10. 2021 ... Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered ...Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in ...Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. The Company develops, manufactures, and commercializes, for itself or with partners, therapeutic …Antares Pharma Inc is a specialty pharmaceutical company. It is focused on the development and commercialization of self. Pharmaceuticals. Ewing, NJ. 203 As of 2021 00000. 0.000 0000-00-00. 000000&0 00000. 000000. ore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, su. 000000000000000. Bolton, Canada. …Otrexup™ Methotrexate, Preservative Free 15 mg / 0.4 mL Injection Prefilled Auto-Injector 4 Devices Antares Pharma Inc 54436001504.Mar 3, 2022 · EWING, NJ, March 3, 2022 – Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today reported financial and operating results for the fourth quarter ended December 31, 2021 with record revenue of $48.7 million, net income of $32.7 million, or $0.19 per diluted earnings per share, and adjusted net income of $4.1 million, or $0.02 per adjusted diluted ... Oct 1, 2018 · Antares Pharma, Inc. is a specialty pharmaceutical company focused on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery ...

Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas.Through our recent acquisition of Antares Pharma, Inc. (“Antares”), we also develop, manufacture and commercialize, for ourselves or with our partners, drug-device combination products using our advanced auto-injector technologies that are designed to provide commercial or functional advantages such as convenience, improved tolerability, …Apr 13, 2022 · SAN DIEGO and EWING, N.J., April 13, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") and Antares Pharma, Inc. (NASDAQ: ATRS) ("Antares") today announced that the... Jun 28, 2021 · Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in ... Aug 10, 2020 · Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ... Antares Pharma Inc is a specialty pharmaceutical company. It is focused on the development and commercialization of self. Pharmaceuticals. Ewing, NJ. 203 As of 2021 00000. 0.000 0000-00-00. 000000&0 00000. 000000. ore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, su. 000000000000000. Bolton, Canada. …13. 4. 2022 ... Antares Pharma to be acquired by Halozyme in $960M deal ... Robert Apple, CEO of Antares Pharma. ... Antares, which was originally founded in Exton, ...

Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. The Company develops, manufactures, and commercializes, for itself or with partners, therapeutic …Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and …

EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (AMEX: AIS - News) today announced the appointment of Paul K. Wotton, Ph.D., as the Company’s President and Chief Executive Officer effective immediately. Dr. Wotton previously served as President and Chief Operating Officer. Concurrently, Jack E. Stover has resigned as both …Antares Pharma Drug Delivery Platforms. With over 30 years of experience in device development engineering our internal development team specializes in creating custom designed drug delivery devices that are tailored to the patient and the therapeutic need.The Antares Pharma Inc PEG ratio, or Antares Pharma Inc (price / earnings to growth) ratio, is a measure that helps Antares Pharma Inc investors value the Antares Pharma Inc business by taking into consideration the Antares Pharma Inc stock market price, earnings, and future growth potential of Antares Pharma Inc as a business.Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...Pharmaceuticals, Inc. to make all required payments under the agreements; uncertainties regarding future FDA approval of TLANDO®, market acceptance and future revenue from the same, whether Antares will exercise the option for LPCN 1111 (TLANDO XR) and if exercised, future timing and success of theAntares Pharma Inc., Glide Pharmaceutical Technologies Ltd., Injex Pharma AG, Pharmajet, In .are some of the major players in the global market. Related Reports Limb Prosthetics MarketAntares Pharma, Inc. (NASDAQ:ATRS) issued its quarterly earnings data on Thursday, November, 4th. The specialty pharmaceutical company reported $0.03 EPS for the quarter, meeting the consensus estimate of $0.03. The specialty pharmaceutical company earned $48.19 million during the quarter, compared to the consensus estimate …Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) _____ Delaware: 001-32302: 41-1350192 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 100 Princeton South, Suite 300, Ewing, NJ ...

Becton, Dickinson and Company, Sanofi, Pfizer, Inc, Mylan N.V., Novartis AG, Bayer AG, Janssen Global Services, LLC, Antares Pharma, Inc., Amgen Inc, Eli Lilly and Company, Teva Pharmaceutical, Merck KgaA, GlaxoSmithKline plc, Ypsomed, SHL Medical, Gerresheimer AG, Midas Pharma GmbH, Aptar Pharma, Solteam Medical, …

Apr 13, 2022 ... offered to acquire specialised biopharmaceutical business Antares Pharma Inc. for roughly 1 billion dollars. Halozyme released a Statement ...

Delaware . 1-32302 . 41-1350192 (State or Other Jurisdiction. of Incorporation) (Commission. File Number) (I.R.S. Employer. Identification No.) 100 Princeton South ...Minnetonka, Minnesota (763) 475-7700 12500 Whitewater Drive Minnetonka, MN 55343 USAAntares Pharma, Inc. (Amex:AIS) today announced an agreement with Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) to provide its needle-free injection system exclusively for use with a currently unnamed product in the U.S. Under the terms of the agreement, Teva will purchase all of its requirements for the injection system from …Antares Pharma, Inc. (“Antares,” “we,” “our,” “us” or the “Company”) is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in targeted therapeutic areas.Oct 1, 2018 · Antares Pharma, Inc. is a specialty pharmaceutical company focused on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery ... EBITDA of $420 million to $440 million, representing growth of >30% over 2022. EBITDA excludes the impact of amortization costs related to the Antares Pharma acquisition.1 Non-GAAP diluted earnings per share of $2.65 to $2.75, representing growth of 20% over 20221.Lincare Inc. sells oxygen and infusion systems for in-home respiratory therapy. Some of the oxygen systems include concentrators, portable and stationary liquid oxygen systems and high-pressure systems.Antares Pharma, Inc. (“Antares,” “we,” “our,” “us” or the “Company”) is an emerging, specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies.Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. The Company develops, manufactures and commercializes, for itself or with partners, novel therapeutic …Overview. Company Description: Antares Pharma understands antagonism towards needles. The company develops needle-free systems for administering injectable drugs. …Antares Pharma, Inc. is a combination drug device company focused on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery auto ...Jan 26, 2016 · Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas.

Antares Pharma, Inc. v. Medac Pharma Inc., 771 F.3d 1354, 1362 (Fed. Cir. 2014). As a result, the Court has previously held that the satisfaction of the requirements under 35 U.S.C. §251 is analogous to the requirements under 35 U.S.C. §112(a).Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...Antares Pharma, Inc. (NYSE Amex: AIS) today announced that it has licensed to Pfizer Inc.’s Consumer Healthcare Business Unit one of its drug delivery technologies to develop an undisclosed product on an exclusive basis for North America. Pfizer will assume full cost and responsibility for all clinical development, manufacturing, …Instagram:https://instagram. how to trade with forexcompanies investing in real estatehealthcare worker mortgage loansbest crypto on robinhood Antares Pharma is a leading company in the development and commercialization of self-administered injectable products. Learn more about its innovative portfolio, pipeline and financial performance in this investor presentation from January 2022. Assertio Holdings, Inc. to make all required payments under the agreements for OTREXUP®; uncertainties regarding future FDA approval of TLANDO®, market acceptance and future revenue from the same, whether Antares will exercise the option for LPCN 1111 (TLANDO XR) and if exercised, future timing and success of the clinical development anhesuer busch stockstock palo alto Our multi-use, disposable pen injector complements our portfolio of single-use pressure assisted auto injector devices. The disposable pen injector device is designed to deliver drugs by injection through needles from multi-dose cartridges. Our disposable pen injector is designed for chronic conditions such as diabetes, which require daily ... nyse knx Follow. EWING, N.J., March 29, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug ...About Antares Pharma . Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas.